Carvedilol Inhibits Basal and Stimulated ACE Production in Human Endothelial Cells

Journal of Cardiovascular Pharmacology

Volumn 43, Issue 5, 2004, Pages 616-621

  Saijonmaa, Outi ^a   Nyman, Tuulikki ^a   Fyhrquist, Frej ^a  

^a MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

Author keywords

ACE; Carvedilol; HUVEC; PKC; Renin angiotensin system

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE; METOPROLOL; NICARDIPINE; PHORBOL 13 ACETATE 12 MYRISTATE; PRAZOSIN; PROBUCOL; PROPRANOLOL; PROTEIN KINASE C; VASCULOTROPIN;

ADRENERGIC RECEPTOR BLOCKING; ARTICLE; CARDIOVASCULAR DISEASE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION;

CARBAZOLES; CARDIOVASCULAR AGENTS; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOBLOTTING; PEPTIDYL-DIPEPTIDASE A; PHOSPHORYLATION; PROPANOLAMINES; PROTEIN KINASE C; RNA, MESSENGER; TETRADECANOYLPHORBOL ACETATE; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATOR AGENTS;

EID: 2042498830     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200405000-00002     Document Type: Article

References (27)

1. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
2. Feurstein GZ, Ruffolo RR. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J. 1995;16(Suppl.F):38-42.
3. Ohlstein E, Vickery L, Arleth A, et al. Carvedilol, a novel cardiovascular agent, inhibits development of vascular and ventricular hypertrophy in spontaneously hypertensive rats. Clin Exp Hypertens. 1994;16:163-177.
4. Frishman W. Drug therapy: carvedilol. N Engl J Med. 1998;339:1759-1765.
5. Ohlstein EH, Douglas SA, Sung C-P, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA. 1993;90:6189-6193.
6. Yue T-L, Wang X, Gu J-L, et al. Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Eur J Pharmacol. 1995;294:585-591.
7. Sijonmaa O, Metsärinne K, Fyhrquist F. Carvedilol and its metabolites suppress endothelin-1 production in human endothelial cell culture. Blood Press. 1997;6:24-28.
8. Ohlstein E, Arleth A, Storer B, et al. Carvedilol inhibits endolhelin-1 biosynthesis in cultured human coronary artery endothelial cells. J Mol Cell Cardiol. 1998;30:167-173.
9. Weiss D, Sorescu D, Taylor R. Angiotensin II and atherosclerosis. Am J Cardiol. 2001;87(suppl):25C-32C.
10. Skidgel R, Erdös E. Biochemistry of angiotensin I-converting enzyme. In: The renin-angiotensin system. Robertson I, Nicholls G, eds. London: Gower Medical; 1993:1;10.1-10.10.
11. Chobanian A, Haudenschild C, Nickerson C, et al. Antiatherogenic effect of captopril in the watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15:327-331.
12. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-ananlysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
13. Jaffe E, Nachman R, Becker C, et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756.
14. Fyhrquist F, Tikkanen I, Grönhagen-Riska C, et al. Inhibitor binding assay for angiotensin converting enzyme. Clin Chem. 1984;30:696-700.
15. Saijonmaa O, Fyhrquist F. Upregulation of angiotensin converting enzyme by atrial natriuretic peptide and cyclic GMP in human endothelial cells. Cardiovasc Res. 1998;40:206-210.
16. Jackson B, Cubela R, Johnston C. Characterization of angiotensin converting enzyme from rat tissue by radio-inhibitor binding studies. Clin Exp Pharmacol Physiol. 1986;13:681-689.
17. Watanabe K, Lam G, Keresztes R, et al. Lipopolysaccharides decrease angiotensin converting activity expressed by cultured human endothelial cells. J Cell Physiol. 1992;150:433-439.
18. Louis W, Menell J, Workman B, et al. A pharmacokinetic study of carvedilol (BM 14190) in elderly subjects: Preliminary repont. J Cardiovasc Pharmacol. 1987;10:S89-S93.
19. Nakamura K, Kusano K, Nakamura Y, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation. 2001;105:2867-2871.
20. Feuerstein G, Bril A, Ruffolo R. Protective effects of carvedilol in the myocardium. Am J Cardiol. 1997;80:41L-45L.
21. Yue T, Wang X, Gu J-L, et al. Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Eur J Pharmacol. 1995;294:585-591.
22. Villard E, Alonso A, Agrapart M, et al. Induction of angiotensin I-converting enzyme transcription by a protein kinase C-dependent mechanism in human endothelial cells. J Biol Chem. 1998;273:25191-25197.
23. Saijonmaa O, Nyman T, Kosonen R, et al. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. Am J Physiol. 2001;280:H885-H891.
24. Eriksson U, Danilezyk U, Penninger J. Just the beginning: Novel function for angiotensin-converting enzymes. Curr Biol. 2002;12:R745-R752.
25. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J Am Med Assoc. 1995;273:1450-1456.
26. Poole-Wilson P, Swedberg K, Cleland J, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:n7-13.
27. Forslund T, Fyhrquist F, Grönhagen-Riska C, et al. Induction of angiotensin-converting enzyme with the ACE inhibitory compound MK-421 in rat lung. Eur J Pharmacol. 1982;80:121-125.